Business
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the 46th Annual TD Cowen Healthcare Conference, being held in Boston, MA, on Monday, March 2, 2026 at 11:10 a.m. E
About this update from Metagenomi Therapeutics, Inc.
[{"type":"image","alt":"Metagenomi, Inc.","displaySize":"","headline":null,"caption":"Metagenomi, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/8fe98471f37fe1fb8aa0158e0a6364b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EWBRQhbSdkPvTJp6aTx5mw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/8fe98471f37fe1fb8aa0158e0a6364b1","width":300,"height":50}},"lazy":false},{"type":"text","content":"EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the 46th Annual TD Cowen Healthcare Conference, being held in Boston, MA, on Monday, March 2, 2026 at 11:10 a.m. ET.","length":502,"tagName":"p","attribs":{}},{"type":"text","content":"The fireside chat presentation will be made available on the “News & Events” page in the Investors section of the Company’s website at https://ir.metagenomi.co/news-events/events.","length":183,"tagName":"p","attribs":{}},{"type":"text","content":"About Metagenomi Therapeutics, Inc.","length":35,"tagName":"p"},{"type":"text","content":"Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, integration and correction.","length":788,"tagName":"p"},{"type":"text","content":"MGX-001, the Company’s lead, wholly-owned development program in hemophilia A, has demonstr...